A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo

Sponsor
Peking University Third Hospital
Study ID
NCT07153666
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Vitiligo is a common chronic autoimmune skin disease that can occur on any part of the body and severely impacts patients' quality of life. Current treatment for vitiligo primarily include topical medications, phototherapy, systemic therapy and surgical interventions, but their efficacy is limited, often failing to achieve ideal therapeutic outcomes, and are associated with a high recurrence rate. This study is an investigator-initiated real-world research on the application of ruxolitinib cream for vitiligo treatment, with the primary objective of exploring the factors influencing the efficacy of ruxolitinib cream in treating vitiligo.

Key Dates

Start date
Dec 8, 2025
Status verified
Dec 2025
Primary completion
Jun 30, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
170 participants (estimated)

Arms

  • Arm: ruxolitinib
    ruxolitinib twice per day

Primary Outcome Measure

the proportion of achieving T-VASI50 (50% improvement of total vitiligo area scoring index T-VASI) [ Time Frame: Week 24 ]

Central Contacts

Related Studies